AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions	, and listings, of claims in the application.
[

- 1. (canceled)
- 2. (canceled)
- 3. (canceled)
- 4. (canceled)
- 5. (canceled)
- 6. (canceled)
- 7. (canceled)
- 8. (canceled)
- 9. (canceled.)
- 10. (canceled)
- 11. (New) A recombinant adenovirus containing an expression vector comprising P972 gene and a promoter operably linked to the P972 gene, wherein said adenovirus is capable of infecting mammalian cells.
- 12. (New) The recombinant adenovirus of claim 11, wherein the adenovirus is AdP972 and has Accession No. KCTC 0806BP.
- 13. (New) The recombinant adenovirus of claim 11, wherein the P972 gene is wild-type human P972 cDNA.
 - 14. (New) A mammalian cell transformed with the adenovirus of claim 11.
 - 15. (New) The mammalian cell of claim 14, wherein the cell is a human cell.

Application No.: 10/089,641 4 Docket No.: 06181/000K439-US0

16. (New) The mammalian cell of claim 15 wherein the cell is a cancer cell.

17. (New) The human cell of claim 15, wherein the cell is a cancer cell.

18. (New) The human cell of claim 15, wherein the cancer cell is selected from a breast cancer cell, a colon cancer cell or a cervical cancer cell.

19. (New) A method of treating cancer in a mammal in need thereof, comprising directly administering to the mammal an effective amount of the recombinant adenovirus of claim 11.

20. (New) A method of treating cancer in a mammal in need thereof, comprising directly administering to the mammal the recombinant adenovirus of claim 12.